Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 18/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 16/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.53 |
| ▸ | QPCT | Q16769 | 1/20 | 0.53 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.53 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.53 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10646248 | 0.79 | HTT (0.48) | MAPT | |
| SCHEMBL13907297 | 0.77 | CYP11B1 (0.68) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| SCHEMBL9664139 | 0.77 | CYP11B1 (0.49) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| SCHEMBL448303 | 0.77 | HTT (0.50) | MAPT | |
| SCHEMBL9198880 | 0.75 | EGLN3 (0.49) | CYP19A1TBXAS1 | |
| SCHEMBL11308705 | 0.75 | CYP11B1 (0.40) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| SCHEMBL10926603 | 0.75 | AGER (0.48) | CYP19A1POLB | |
| SCHEMBL1334550 | 0.74 | CYP11B1 (0.67) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| Hydrochloric Acid SCHEMBL9123187 | 0.74 | EGLN3 (0.48) | TBXAS1 | |
| SCHEMBL2728903 | 0.71 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779565-B2 | Small organic molecules for use in the treatment of neuroinflammatory disorders | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center (IL) | 2023-10-10 | — | — | US | disclosed |
| CN-1284066-A | Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors | ALLERGEN SALES INC (US) | 2001-02-14 | — | — | CN | disclosed |
| EP-0244803-B1 | Novel dopamine beta hydroxylase inhibitors | MERRELL DOW PHARMA (US) | 1994-10-26 | — | — | EP | disclosed |
| EP-0301456-B1 | Novel (aryl or heteroaromatic methyl)-2,2'-BI-1H-imidazoles | MERRELL DOW PHARMA (US) | 1994-02-02 | — | — | EP | disclosed |
| CN-1016173-B | NOVEL (ARYL OR HETERVAROMATIC METHYL) -2,2'-BI-1H-IMIDAZOLES PROCESS | MERRELL DOW PHARMA (US) | 1992-04-08 | — | — | CN | disclosed |
| US-5017591-A | Enzyme inhibitors | MERRELL DOW PHARMACEUTICALS (US) | 1991-05-21 | — | — | US | disclosed |
| CN-1034718-A | Novel (aryl or heteroaryl methyl)-2,2 '-two-1H-imidazoles | MERRELL DOW PHARMA (US) | 1989-08-16 | — | — | CN | disclosed |
| US-4839375-A | (Aryl or heteroaromatic methyl)-2,2'-bi-1H-imidazoles and their use as anti-hypertensive agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-06-13 | — | — | US | disclosed |
| US-4810800-A | HYPOTENSIVE AGENTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-03-07 | — | — | US | disclosed |
| EP-0301456-A2 | Novel (aryl or heteroaromatic methyl)-2,2'-BI-1H-imidazoles | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-02-01 | — | — | EP | disclosed |
| CN-87103323-A | The method for preparing new Dopamine HCL, hydroxylase inhibitors | — | 1988-02-03 | — | — | CN | disclosed |
| EP-0244803-A2 | Novel dopamine beta hydroxylase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-11-11 | — | — | EP | disclosed |
| EP-0071059-B1 | 6-(5-(OMEGA-(1-IMIDAZOLYL)-ALKYL)-THIEN-2-YL)-3-OXO-2,3,4,5-TETRAHYDROPYRIDAZINES AND THEIR ACID-ADDITION SALTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOUNDS CONTAINING THEM | A. Nattermann & Cie. GmbH (DE) | 1986-09-24 | — | — | EP | disclosed |
| US-4504479-A | 6-{5-[ω-(1-Imidazolyl)-alkyl]-thien-2-yl}-3-oxo-2,3,4,5-tetrahydro-pyridazines and acid addition salts thereof and a process for the treatment of inflammatory atherosclerotic and thrombo-embolic, illnesses in humans | A. NATTERMANN & CIE GMBH (DE) | 1985-03-12 | — | — | US | disclosed |
| EP-0071059-A2 | 6-(5-(Omega-(1-imidazolyl)-alkyl)-thien-2-yl)-3-oxo-2,3,4,5-tetrahydropyridazines and their acid-addition salts, process for their preparation and pharmaceutical compounds containing them | A. Nattermann & Cie. GmbH (DE) | 1983-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11779565-B2 | Small organic molecules for use in the treatment of neuroinflammatory disorders | BMP1, BMP2, BMP4 | CYP11B1 3064/4885CYP11B2 2618/4885CYP19A1 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.